Regeneron starts late-stage tests of Covid-19 antibody
Regeneron Pharmaceuticals announced this morning it is starting tests aimed at proving that its antibody drug can both treat and prevent SARS-CoV-2, the virus that causes Covid-19.
One trial, run by Regeneron alone, will test the company's cocktail of two antibodies as a treatment for hospitalized and non-hospitalized Covid-19 patients. A second study, being run by the National Institute of Allergy and Infectious Disease, part of the National Institutes of Health, will look at whether the antibody cocktail can prevent infection with SARS-CoV-2. The prevention trial will be run at 100 sites in the U.S.; the treatment study is being run at 150 sites in the U.S., Brazil, Mexico, and Chile, with preliminary results due by the end of the summer.
Monoclonal antibodies are proteins produced by the immune system that can neutralize pathogens; similar approaches are being taken by Eli Lilly and Abcellera and Vir and GlaxoSmithKline.
Last week, Regeneron reported that a trial of Kevzara, a rheumatoid arthritis drug it sells with partner Sanofi, did not help hospitalized Covid-19 patients in a U.S. study. A study of Kevzara in hospitalized patients outside the U.S. is still ongoing.
One trial, run by Regeneron alone, will test the company's cocktail of two antibodies as a treatment for hospitalized and non-hospitalized Covid-19 patients. A second study, being run by the National Institute of Allergy and Infectious Disease, part of the National Institutes of Health, will look at whether the antibody cocktail can prevent infection with SARS-CoV-2. The prevention trial will be run at 100 sites in the U.S.; the treatment study is being run at 150 sites in the U.S., Brazil, Mexico, and Chile, with preliminary results due by the end of the summer.
Monoclonal antibodies are proteins produced by the immune system that can neutralize pathogens; similar approaches are being taken by Eli Lilly and Abcellera and Vir and GlaxoSmithKline.
Last week, Regeneron reported that a trial of Kevzara, a rheumatoid arthritis drug it sells with partner Sanofi, did not help hospitalized Covid-19 patients in a U.S. study. A study of Kevzara in hospitalized patients outside the U.S. is still ongoing.
No hay comentarios:
Publicar un comentario